IRLAB Therapeutics AB announced that all participating study sites in the Phase IIb study of pirepemat (IRL752) are activated and recruiting patients. The study is conducted at 38 study sites across six European countries. Pirepemat has the potential to become the first treatment in a new class of drugs designed to improve balance and reduce falls and fall injuries in people living with Parkinson's disease.

The Phase IIb study of pirepemat is a randomized, double-blind, and placebo-controlled study with the aim to evaluate the effect of pirepemat on falls frequency, postural dysfunction, cognitive function, symptoms of Parkinson's disease as well as safety and tolerability, in people with Parkinson's disease. The study is active at 38 study sites across France, Germany, Poland, the Netherlands, Spain, and Sweden. Patient recruitment and randomization are expected to be completed by the year-end of 2023 followed by the three-month treatment period, follow-up visits, data management, and database lock.

Top-line results are further expected in first half of 2024.